Navigation Links
Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections
Date:9/27/2010

SAN DIEGO, Sept. 27 /PRNewswire/ -- Clinicians from three U.S. hospitals today reported significant progress in the fight against deadly IV catheter-related bloodstream infections (CRBSI). Data analyzed and presented by clinicians from St. Joseph's Mercy Hospital in Hot Springs, Ark.; Bethesda North Hospital in Cincinnati; and the VA Medical Center in Seattle showed that the hospitals virtually eliminated such infections, which annually kill some 62,500 hospital patients nationwide.

(Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100706/CAREFUSIONLOGO)

The new findings are noteworthy because few U.S. hospitals have been able to achieve greater than an 80 percent reduction in CRBSI rates. Clinical research, presented Sept. 25 at the annual meeting of the Association for Vascular Access, document the effectiveness of the CareFusion MaxPlus Clear positive displacement needleless access connector in combination with clinical practices. The results further support use of MaxPlus® technology to assist in central line-associated bloodstream infections (CLABSI) reduction efforts; eight additional research reports, either published or presented, show virtually the same results.

CareFusion's MaxPlus Clear technology provides a visual cue to perform best practices more thoroughly including priming, disinfection and flushing and therefore helps promote the performance of best practices. In addition, the smooth top provides an optimal surface for easy disinfection.

Annually, CRBSIs affect 250,000 U.S. hospital patients; about 25 percent of such cases result in death. In addition to the human toll, the financial costs to the health care system are staggering. These preventable infections typically increase a patient's hospital stay by anywhere from 10 to 24 days. (1)

The U.S. Centers for Medicare and Medicaid Services have identified CRBSI as a "never event," implementing more stringent reimbursement requirements for care related to such cases. A single incident of CRBSI can cost as much as $56,000 to treat, based on the costs associated with pharmacy charges, catheter changes, lab tests and an additional day in the ICU. (2)

Clinical findings

Patricia Gould, RN, Infection Preventionists at St. Joseph's Mercy Health Center reported dropping from 4.08 CLABSIs per 1000 catheter days to zero and maintaining the rate of zero for a total of 20 months with the implementation of an evidence based "bundle," including the use of the MaxPlus Clear connector.

Similarly, Tim Royer, retired nurse manager of vascular access, discussed interventions that led to the elimination of CRBSIs in the Intensive, Medical-Surgical, Spinal Cord Injury and Transitional Care Units for 17 months at the VA Medical Center Seattle.

"Blood and debris are a growth media for bacteria," said Royer. "An impressive continued drop to zero CRBSI rate was noted through the implementation of a clear, swabable, positive displacement needleless connector as a cue to clean, flush and change the valve. If the valve is opaque, it does not trigger or reinforce the process to keep blood and debris out of the catheter."

In addition, Jennifer McCord, BSN, RN, PCCN, CCRN, CCNS of Bethesda North Hospital reported 12 less CRBSIs in 2009 vs. 2008 and rates dropped from 1.955 to 0.369 per 1000 catheter days representing an 81 percent reduction in CRBSIs. The hospital implemented a nurse-driven peripherally inserted central catheter (PICC) team, along with the CareFusion MaxPlus Clear connector. These protocols are estimated to save the hospital up to $600,000 per year.

More about MaxPlus technology

CareFusion markets patented needleless connector technology designed to help health care providers. MaxPlus and MaxGuard® brands of needleless IV connectors are clinically shown to help reduce CRBSIs, reduce catheter occlusions and improve outcomes, costs and enhance safety.

CareFusion recently added these brands to the infusion business portfolio through the acquisition of Medegen in April 2010.

About CareFusion

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined™ services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.

(1) O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. "Guidelines for the Prevention of Intravascular Catheter-related Infections." The Centers for Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 1-26.

(2) O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. "Guidelines for the Prevention of Intravascular Catheter-related Infections." The Centers for Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 1-26.


'/>"/>
SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):